Eli Lilly and Company (LLY)vsInnovative Eyewear Inc. (LUCY)
LLY
Eli Lilly and Company
$934.60
+9.80%
HEALTHCARE · Cap: $760.43B
LUCY
Innovative Eyewear Inc.
$1.05
+0.96%
HEALTHCARE · Cap: $6.49M
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 2448673% more annual revenue ($65.18B vs $2.66M). LLY leads profitability with a 31.7% profit margin vs -285.2%. LLY earns a higher WallStSmart Score of 78/100 (B+).
LLY
Strong Buy78
out of 100
Grade: B+
LUCY
Hold36
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LLY.
Margin of Safety
+39.2%
Fair Value
$1.81
Current Price
$1.05
$0.76 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 101 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 44.9%
Revenue surging 42.6% year-over-year
Earnings expanding 51.4% YoY
Reasonable price relative to book value
Revenue surging 39.0% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 31.5x book value
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -83.6% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.7% and operating margin at 44.9%. Revenue growth of 42.6% demonstrates continued momentum.
Bull Case : LUCY
The strongest argument for LUCY centers on Price/Book, Revenue Growth. Revenue growth of 39.0% demonstrates continued momentum.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.60 is elevated, increasing financial risk.
Bear Case : LUCY
The primary concerns for LUCY are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
LLY profiles as a growth stock while LUCY is a hypergrowth play — different risk/reward profiles.
LUCY carries more volatility with a beta of 3.06 — expect wider price swings.
LLY is growing revenue faster at 42.6% — sustainability is the question.
LLY generates stronger free cash flow (678M), providing more financial flexibility.
Bottom Line
LLY scores higher overall (78/100 vs 36/100), backed by strong 31.7% margins and 42.6% revenue growth. LUCY offers better value entry with a 39.2% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Innovative Eyewear Inc.
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Innovative Eyewear Inc. (LUCY) is a pioneering player in the smart eyewear sector, skillfully merging advanced technology with modern aesthetics to meet the needs of tech-savvy consumers. Its flagship line, Lucyd, stands out by integrating audio features and connectivity into stylish eyewear, thus providing both versatility and fashion. With a strong focus on innovation and enhancing user experiences, the company is well-positioned to harness the growing demand for multifunctional wearables, indicating significant growth potential in the rapidly evolving eyewear market. As trends shift towards smart solutions, LUCY's strategic approach positions it favorably for long-term success.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?